T
he Journal of Biomolecular Screening (JBS) continues to gain importance as an internationally respected peerreviewed journal. In 2004, the journal grew from 6 to 8 issues per year. Its importance is further illustrated in the last quarterly report, which showed the increasing number of manuscripts received for review, the rise in quality of scientific data and results, the escalation in the impact factor to 2.933 in 2003 (up from 2.066 in 2002), and advertising sales that continue to climb. The online version of JBS has migrated from Ingenta to HighWire, which offers access to a large number of scientific publications. We expect that our move to HighWire will increase external access to JBS and further enhance its ranking. Steps are also being taken to bring the early volumes of JBS online so that the complete publication is available in a searchable format. Larry Walker, JBS Editor-in-Chief, is to be commended for his direction and leadership, which have helped to drive the publication forward. We also owe a debt of gratitude to our advertisers who support the efforts of the Society for Biomolecular Screening (SBS) and its journal. The readership values information on the newest products and services, and JBS serves as an excellent vehicle to deliver that information.
SBS News likewise has increased from 5 to 6 issues in 2004. We have begun evaluating whether to offer advertising opportunities in SBS News and maintain print copy or to redesign the publication for electronic distribution. The advantages and disadvantages will need to be weighed carefully, and I would like to hear from you if you have strong feelings about converting to electronic format or maintaining SBS News in print.
REPRINTS OF THE COMMEMORATIVE 10 TH ANNIVERSARY AWARDS BOOKLET
In celebration of our 10th anniversary, an awards booklet was published to highlight some of the significant contributions that have taken place over the past decade and to recognize those innovators who have been driving the science and technology forward. These booklets were distributed at the annual conference in Orlando, but if you did not receive a copy, you may request one from the SBS office by contacting Kat Harrison (kharrison@ sbsonline.org).
CONFERENCE UPDATES
Conference planning is going well, and we are pleased to present 4 dynamic keynote speakers who will delve into the future of drug discovery. Professor Klaus Lindpaintner, head of Roche Genetics and the Roche Center for Medical Genomics, will present "Biomarkers: Hype, Hope and the Reality of Health Care"; Chris Austin of the National Institutes of Health (NIH) will discuss "The NIH Molecular Libraries Roadmap Initiative"; Professor Kurt Wüthrich of the Institute of Molecular Biology and Biophysics will address "NMR for Screening and Structure Determination in Structural Genomics"; and Gunther Stock, CSO of Schering AG, will present "The Biomedical Century and Its Opportunities for Drug Development."
The Virtual Trade Show is available on the SBS Web site (www.sbsonline.org). It offers prospective customers an opportunity to visit with companies that are exhibiting at the SBS Conference in Geneva. Each participating company has a link to its Web site, and conference attendees can dialogue with sales representatives, read company press releases, and learn about new products and services that will be previewed at the conference. All this information, coupled with the convenience of an itinerary planner, will help optimize your time at the conference.
ELECTIONS
SBS is in search of a few good leaders who wish to contribute to the future direction of SBS. Each year at the annual business meeting, 3 members of the board retire after having served for 3 years. The ideal candidates for the board are progressive, visionary leaders with a strong knowledge of the industry. Working in partnership with SBS's executive director, the board's role is to think strategically and to set policy, define scientific direction, and ensure the organization's continued success. Candidates must be current members of SBS who bring real-world experience to the organization and can help set the course to develop future programs, products, and services.
The governing philosophy is based on
• outward vision focused on the future, • encouraging diversity in viewpoints, • strategic leadership,
• respect for the role of the board and chief staff executive, • collective decision making, and • being proactive rather than reactive.
There are 4 core values that represent the essential and enduring principles that define the essence of the society and the experience we offer our members: scientific integrity and excellence, openness to new ideas, respect for all voices, and a rewarding and enjoyable experience.
Members of the governing board must be
• able and willing to attend quarterly meetings of the board;
• current on issues and trends influencing the industry, society, and SBS membership and ensure that the needs of the members-identified through the analysis of market research-are met;
• familiar with governance and understand the organization's mission, vision, and financial position; • actively involved in deliberations and able to reach decisions as an independent entity, deliberately and without haste, supporting the consensus of the board; • willing to undertake fiduciary responsibilities to review, discuss, and approve the annual budget; • active in promoting the discipline of drug discovery and the society's image and helping recruit new leaders; and • capable of giving guidance to the working committees to maintain relevance, further educational goals, and advance membership.
Key issues the governing board is exploring include the following:
• What will drug discovery look like over the next 10 years?
• Should SBS expand to cover a broader section of drug discovery?
Will staying within the boundaries of biomolecular screening limit our opportunities for growth? • How can we help to create the next generation of scientists skilled in molecular discovery and facilitate increased communication between industry and academia?
If you are interested in serving, please submit a brief biography (150 words or less), along with a statement describing why you want to serve on the board and what you hope to accomplish. Your qualifications should be sent by e-mail to kharrison@ sbsonline.org by June 1, 2005. Voting will take place online, and the successors will be notified in writing in August.
WE WANT TO HEAR FROM YOU
Before I close, there have been a number of articles written about the future of SBS and its changing role in drug discovery. If you have not had an opportunity to respond to any of the articles that are exploring a name change, we'd like to hear from you. Your comments should be sent to email@sbsonline.org. We will also be running some survey questions on the home page of the SBS Web site. Each set of questions will be posted for 1 month before changing to a new set of questions. We ask that you invest a few moments of your time to respond to these online surveys so we can better assess your wants and needs. The questions currently posted will help the Education Committee assess what educational materials are missing from our list of products and what format you would find most beneficial for use by yourself and/or your colleagues.
Respectfully submitted,
Christine Giordano, CAE
Executive Director
